Improving outcomes after autologous transplantation in relapsed/refractory Hodgkin lymphoma: a European expert perspective

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1471-2407
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
Improving outcomes after autologous transplantation in relapsed/refractory Hodgkin lymphoma: a European expert perspective ; volume:20 ; number:1 ; day:10 ; month:11 ; year:2020 ; pages:1-14 ; date:12.2020
BMC cancer ; 20, Heft 1 (10.11.2020), 1-14, 12.2020

Urheber
Sureda, Anna
André, Marc
Borchmann, Peter
Silva, Maria G. da
Gisselbrecht, Christian
Vassilakopoulos, Theodoros P.
Zinzani, Pier Luigi
Walewski, Jan
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1186/s12885-020-07561-2
URN
urn:nbn:de:101:1-2020122123264959695180
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
15.08.2025, 07:22 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Sureda, Anna
  • André, Marc
  • Borchmann, Peter
  • Silva, Maria G. da
  • Gisselbrecht, Christian
  • Vassilakopoulos, Theodoros P.
  • Zinzani, Pier Luigi
  • Walewski, Jan
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Analysis of Relapsed/Refractory Hodgkin Lymphoma Treated with Autologous Transplantation: A Single-Center Experience

Analysis of Relapsed/Refractory Hodgkin Lymphoma Treated with Autologous Transplantation: A Single-Center Experience

Fluorodeoxyglucose-Positron Emission Tomography in Relapsed/Refractory Hodgkin Lymphoma: A Practical Approach

Fluorodeoxyglucose-Positron Emission Tomography in Relapsed/Refractory Hodgkin Lymphoma: A Practical Approach

High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin Lymphoma

High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin Lymphoma

BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience

BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience

Characteristics and outcomes of children, adolescents and young adults with relapsed/refractory non-hodgkin lymphoma undergoing autologous stem cell transplant

Characteristics and outcomes of children, adolescents and young adults with relapsed/refractory non-hodgkin lymphoma undergoing autologous stem cell transplant

Checkpoint Inhibitors and the Changing Face of the Relapsed/Refractory Classical Hodgkin Lymphoma Pathway

Checkpoint Inhibitors and the Changing Face of the Relapsed/Refractory Classical Hodgkin Lymphoma Pathway

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

Population pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma

Population pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma

Management of relapsed-refractory diffuse large B cell lymphoma

Management of relapsed-refractory diffuse large B cell lymphoma

Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma

Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma

Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia

Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia

Update on the management of relapsed/refractory chronic lymphocytic leukemia

Update on the management of relapsed/refractory chronic lymphocytic leukemia

Verbundene Objekte